425: ARYA Sciences Acquisition Corp IV Announces Additional Director Nominee and Updates on PIPE Financing for Adagio Medical Business Combination

ARYA Sciences Acquisition Corp IV announces Sandra Gardiner as an additional director nominee for New Adagio and provides updates on PIPE financing, including a potential increase in investment from Perceptive Life Sciences Master Fund.

Summary

• ARYA Sciences Acquisition Corp IV is set to close its business combination with Adagio Medical, Inc.
• Sandra Gardiner has been identified as an additional director nominee for New Adagio, expected to be appointed as a Class III director and chairperson of the audit committee.
• The audit committee will also include Shahram Moaddeb and Timothy Moran.
• Changes to the composition of the compensation committee and the nominating and corporate governance committee have also been agreed upon.
• The compensation committee will be chaired by Shahram Moaddeb, with members Orly Mishan and Timothy Moran.
• The nominating and corporate governance committee will be chaired by Keyvan Mirsaeedi-Farahani, with members Orly Mishan and James L. Cox.
• Perceptive Life Sciences Master Fund is considering increasing its investment in the PIPE Financing to meet a minimum unrestricted cash condition for another investor.
• If the Closing occurs on July 29, 2024, New Adagio would be required to have approximately $32,129,000 of available unrestricted cash for the Contingent Investor to fund its $7,500,000 commitment under the Convertible Security Subscription Agreement.
• Assuming maximum redemptions, no additional financing, and transaction expenses of approximately $14.3 million, Perceptive PIPE Investor may increase its commitment by approximately $9 million, resulting in the issuance of approximately 1,080,000 additional shares.
• The closing is expected to occur on July 29, 2024.
• The $20,000,000 of financing in the form of New Adagio Convertible Notes includes the conversion of the $7,000,000 of 2024 Bridge Financing Notes into New Adagio Convertible Notes and Convert Warrants at Closing, subject to Additional Financing being raised prior to Closing.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting progress towards the business combination and strengthening the board with an experienced director. The potential increase in PIPE financing further supports the deal's completion. However, risks related to redemptions and dilution temper the overall sentiment.

Positives

• The addition of Sandra Gardiner brings significant financial and operational expertise in the life sciences sector to New Adagio's board.
• Potential increase in PIPE financing from Perceptive Life Sciences Master Fund ensures the minimum cash condition is met, de-risking the transaction.
• The business combination is progressing towards closing, providing clarity for investors.

Negatives

• Maximum redemption scenario could lead to increased dilution for existing shareholders due to the potential issuance of additional shares to Perceptive PIPE Investor.
• Transaction expenses are currently estimated at $14.3 million, which could impact the available cash balance at closing.

Risks

• The business combination is subject to risks including failure to obtain shareholder approval, financing, or regulatory approvals.
• Redemption requests from ARYA's public shareholders could impact the available cash at closing.
• Changes to the proposed structure of the business combination could be required.
• Delays in obtaining regulatory approvals could delay the closing.
• New Adagio's ability to remain compliant with debt covenants is a risk.
• The ability to recognize the anticipated benefits of the Business Combination is subject to risks including competition, the ability of New Adagio to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees.
• Adagio or New Adagio may be adversely affected by other economic, business, and/or competitive factors.

Future Outlook

The business combination is expected to close, with New Adagio focusing on expanding its business plans and utilizing the proceeds from the transaction.

Management Comments

• ListCo believes that Sandra Gardiner qualifies to serve as a director of New Adagio due to her broad operational experience in the life sciences sector.

Industry Context

The business combination reflects a trend of SPACs merging with private companies in the healthcare sector to accelerate their growth and access public markets.

Comparison to Industry Standards

• Sandra Gardiner's experience as CFO of Pulse Biosciences and Cutera aligns with industry standards for financial leadership in publicly traded life sciences companies.
• The PIPE financing structure is a common mechanism for SPAC transactions, similar to deals involving companies like Butterfly Network and Quantum-Si.
• The convertible note structure is similar to other deals in the medical device industry, such as those used by companies like Nevro and Inspire Medical Systems.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may experience dilution depending on redemption levels and the potential increase in PIPE financing.
• Employees of Adagio Medical will be integrated into New Adagio.
• Customers and suppliers of Adagio Medical can expect continuity of operations.

Next Steps

• Closing of the business combination.
• Appointment of Sandra Gardiner to the board of directors of New Adagio.
• Potential increase in PIPE financing from Perceptive Life Sciences Master Fund.
• Conversion of 2024 Bridge Financing Notes into New Adagio Convertible Notes and Convert Warrants.

Key Dates